You just read:

Cognition Therapeutics Sees Lilly Solanezumab Clinical Trial Results as Support for its Unique Mechanism for Treatment of Alzheimer's Disease

News provided by

Cognition Therapeutics, Inc.

23 Nov, 2016, 13:56 ET